Header Logo

Connection

Alan Go to Stroke

Back to Details
This is a "connection" page, showing publications Alan Go has written about Stroke.
Alan Go
Connection Strength
13.123
Stroke
  1. Incident Atrial Fibrillation and Risk of Dementia in a Diverse, Community-Based Population. J Am Heart Assoc. 2023 03 21; 12(6):e028290.
    View in: PubMed
    Score: 0.724
  2. Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Stroke. 2023 Mar; 54(3):e75-e85.
    View in: PubMed
    Score: 0.723
  3. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21; 129(3):399-410.
    View in: PubMed
    Score: 0.385
  4. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21; 129(3):e28-e292.
    View in: PubMed
    Score: 0.382
  5. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013 Jun 21; 2(3):e000250.
    View in: PubMed
    Score: 0.369
  6. Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013 Jan 01; 127(1):143-52.
    View in: PubMed
    Score: 0.358
  7. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013 Jan 01; 127(1):e6-e245.
    View in: PubMed
    Score: 0.356
  8. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke. 2012 Oct; 43(10):2788-90.
    View in: PubMed
    Score: 0.348
  9. CHA2DS2-VASc risk scheme: not ready for clinical use. Chest. 2010 Oct; 138(4):1020; author reply 1020-1.
    View in: PubMed
    Score: 0.306
  10. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med. 2009 Nov 23; 169(21):2032; author reply 2033.
    View in: PubMed
    Score: 0.288
  11. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009 Jul; 2(4):297-304.
    View in: PubMed
    Score: 0.279
  12. The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation. N Engl J Med. 2009 May 14; 360(20):2127-9.
    View in: PubMed
    Score: 0.278
  13. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008 Jun; 39(6):1901-10.
    View in: PubMed
    Score: 0.258
  14. Stroke prevention in atrial fibrillation: another step sideways. Lancet. 2008 Jan 26; 371(9609):278-80.
    View in: PubMed
    Score: 0.254
  15. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008; 22(10):815-25.
    View in: PubMed
    Score: 0.253
  16. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005 Sep 20; 112(12):1687-91.
    View in: PubMed
    Score: 0.215
  17. Antithrombotic therapy for stroke prevention in atrial fibrillation. Prog Cardiovasc Dis. 2005 Sep-Oct; 48(2):108-24.
    View in: PubMed
    Score: 0.215
  18. Anticoagulants for stroke prevention in atrial fibrillation: what is the right rate and where do we go from here? Nat Clin Pract Cardiovasc Med. 2005 May; 2(5):226-7.
    View in: PubMed
    Score: 0.210
  19. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care. 2004 Apr; 10(3 Suppl):S58-65.
    View in: PubMed
    Score: 0.195
  20. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26; 290(20):2685-92.
    View in: PubMed
    Score: 0.190
  21. Gaps in guideline-recommended anticoagulation in patients with atrial fibrillation and elevated thromboembolic risk within an integrated healthcare delivery system. BMC Cardiovasc Disord. 2023 11 21; 23(1):578.
    View in: PubMed
    Score: 0.190
  22. Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (O'CAF? trial). Trials. 2023 Mar 31; 24(1):246.
    View in: PubMed
    Score: 0.182
  23. Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Thromb Thrombolysis. 2003 Feb; 15(1):41-6.
    View in: PubMed
    Score: 0.180
  24. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. Am Heart J. 2022 07; 249:76-85.
    View in: PubMed
    Score: 0.170
  25. Sex Differences in Cardiovascular Outcomes in CKD: Findings From the CRIC Study. Am J Kidney Dis. 2021 08; 78(2):200-209.e1.
    View in: PubMed
    Score: 0.159
  26. Antithrombotic therapy in atrial fibrillation. Clin Geriatr Med. 2001 Feb; 17(1):131-47.
    View in: PubMed
    Score: 0.157
  27. Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2021 08; 78(2):226-235.e1.
    View in: PubMed
    Score: 0.156
  28. Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. Eur Heart J Qual Care Clin Outcomes. 2020 10 01; 6(4):263-272.
    View in: PubMed
    Score: 0.153
  29. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000 Jul 04; 102(1):11-3.
    View in: PubMed
    Score: 0.150
  30. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2020 08; 226:85-93.
    View in: PubMed
    Score: 0.148
  31. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 Dec 21; 131(12):927-34.
    View in: PubMed
    Score: 0.145
  32. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2019 12; 12(12):e007612.
    View in: PubMed
    Score: 0.145
  33. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e006212.
    View in: PubMed
    Score: 0.144
  34. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. Am Heart J. 2019 07; 213:81-90.
    View in: PubMed
    Score: 0.138
  35. Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department. West J Emerg Med. 2018 Mar; 19(2):346-360.
    View in: PubMed
    Score: 0.127
  36. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med. 2017 Dec 19; 167(12):845-854.
    View in: PubMed
    Score: 0.125
  37. Blood Pressure and Risk of Cardiovascular Events in Patients on Chronic Hemodialysis: The CRIC Study (Chronic Renal Insufficiency Cohort). Hypertension. 2017 08; 70(2):435-443.
    View in: PubMed
    Score: 0.122
  38. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017 07 01; 3(3):192-197.
    View in: PubMed
    Score: 0.122
  39. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clin Cardiol. 2017 Sep; 40(9):746-751.
    View in: PubMed
    Score: 0.121
  40. Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. J Am Geriatr Soc. 2017 Feb; 65(2):241-248.
    View in: PubMed
    Score: 0.118
  41. Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Heart Assoc. 2016 07 22; 5(7).
    View in: PubMed
    Score: 0.114
  42. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation? Am J Cardiol. 2016 09 01; 118(5):697-9.
    View in: PubMed
    Score: 0.114
  43. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. J Am Coll Cardiol. 2016 05 10; 67(18):2118-2130.
    View in: PubMed
    Score: 0.113
  44. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J. 2016 Nov 07; 37(42):3203-3210.
    View in: PubMed
    Score: 0.111
  45. Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease. J Hypertens. 2016 Feb; 34(2):244-52.
    View in: PubMed
    Score: 0.111
  46. Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll Cardiol. 2016 Jan 26; 67(3):239-47.
    View in: PubMed
    Score: 0.111
  47. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133(4):447-54.
    View in: PubMed
    Score: 0.111
  48. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016 06; 129(6):592-599.e1.
    View in: PubMed
    Score: 0.110
  49. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133(4):e38-360.
    View in: PubMed
    Score: 0.110
  50. Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization. Am Heart J. 2015 Aug; 170(2):400-8.
    View in: PubMed
    Score: 0.105
  51. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul; 170(1):141-8, 148.e1.
    View in: PubMed
    Score: 0.104
  52. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27; 131(4):e29-322.
    View in: PubMed
    Score: 0.102
  53. Intersection of cardiovascular disease and kidney disease: atrial fibrillation. Curr Opin Nephrol Hypertens. 2014 May; 23(3):275-82.
    View in: PubMed
    Score: 0.098
  54. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014 May 20; 129(20):2005-12.
    View in: PubMed
    Score: 0.097
  55. Long-term survival after ischemic stroke in patients with atrial fibrillation. Neurology. 2014 Mar 25; 82(12):1033-7.
    View in: PubMed
    Score: 0.097
  56. Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation. 2013 Sep 10; 128(11):e172-3.
    View in: PubMed
    Score: 0.094
  57. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):461-9.
    View in: PubMed
    Score: 0.092
  58. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013 Jan 15; 127(2):224-32.
    View in: PubMed
    Score: 0.089
  59. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012 Jul; 43(7):1795-9.
    View in: PubMed
    Score: 0.085
  60. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e531S-e575S.
    View in: PubMed
    Score: 0.084
  61. Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012 Jan 03; 125(1):188-97.
    View in: PubMed
    Score: 0.083
  62. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012 Jan 03; 125(1):e2-e220.
    View in: PubMed
    Score: 0.083
  63. Detection of atrial fibrillation after stroke and the risk of recurrent stroke. J Stroke Cerebrovasc Dis. 2012 Nov; 21(8):726-31.
    View in: PubMed
    Score: 0.080
  64. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 01; 123(4):e18-e209.
    View in: PubMed
    Score: 0.078
  65. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011 Jan 04; 154(1):1-11.
    View in: PubMed
    Score: 0.077
  66. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation. 2010 Oct 12; 122(15):1478-87.
    View in: PubMed
    Score: 0.076
  67. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23; 121(7):948-54.
    View in: PubMed
    Score: 0.073
  68. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23; 121(7):e46-e215.
    View in: PubMed
    Score: 0.072
  69. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009 Mar 17; 119(10):1363-9.
    View in: PubMed
    Score: 0.069
  70. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009 Jan 27; 119(3):480-6.
    View in: PubMed
    Score: 0.068
  71. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009 Jan 27; 119(3):e21-181.
    View in: PubMed
    Score: 0.068
  72. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008 Jan 29; 117(4):e25-146.
    View in: PubMed
    Score: 0.063
  73. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007 Feb 06; 115(5):e69-171.
    View in: PubMed
    Score: 0.059
  74. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation. 2006 Jul 11; 114(2):168-82.
    View in: PubMed
    Score: 0.057
  75. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):429S-456S.
    View in: PubMed
    Score: 0.050
  76. Breast vascular calcification and risk of coronary heart disease, stroke, and heart failure. J Womens Health (Larchmt). 2004 May; 13(4):381-9; discussion 390-2.
    View in: PubMed
    Score: 0.049
  77. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11; 349(11):1019-26.
    View in: PubMed
    Score: 0.047
  78. Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women. J Am Coll Cardiol. 2001 Nov 01; 38(5):1297-301.
    View in: PubMed
    Score: 0.041
  79. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 09; 285(18):2370-5.
    View in: PubMed
    Score: 0.040
  80. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439.
    View in: PubMed
    Score: 0.033
  81. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc. 2017 01; 65(1):35-41.
    View in: PubMed
    Score: 0.029
  82. Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals. JAMA Cardiol. 2016 08 01; 1(5):594-9.
    View in: PubMed
    Score: 0.029
  83. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circ Arrhythm Electrophysiol. 2016 06; 9(6).
    View in: PubMed
    Score: 0.028
  84. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016 Apr; 174:29-36.
    View in: PubMed
    Score: 0.027
  85. Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC Study. Am J Nephrol. 2014; 40(5):399-407.
    View in: PubMed
    Score: 0.025
  86. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc. 2013 Feb 01; 2(1):e005694.
    View in: PubMed
    Score: 0.022
  87. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011 Dec 28; 306(24):2673-83.
    View in: PubMed
    Score: 0.021
  88. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011 Sep 11; 478(7367):103-9.
    View in: PubMed
    Score: 0.020
  89. American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation. 2011 Jul 19; 124(3):363-72.
    View in: PubMed
    Score: 0.020
  90. Vision and creation of the American Heart Association pharmaceutical roundtable outcomes research centers. Circ Cardiovasc Qual Outcomes. 2009 Nov; 2(6):663-70.
    View in: PubMed
    Score: 0.018
  91. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 Aug; 120(8):700-5.
    View in: PubMed
    Score: 0.015
  92. Electrocardiographic findings predict short-term cardiac morbidity after transient ischemic attack. Arch Neurol. 2002 Sep; 59(9):1437-41.
    View in: PubMed
    Score: 0.011

© 2024 Kaiser Permanente